Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide for prevention of contrast-induced nephropathy in STEMI patients undergoing PCI
IRCT20230312057694N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of furosemide in myocardial infarction (MI) and contrast-induced nephropathy (CIN), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Mar 2023; status: completed.
02
Drugs
furosemide
03
Conditions
myocardial infarction (MI)contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20230312057694N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230312057694N1.